Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07128589 · ClinicalTrials.gov registry record · NA
3M(TM) Filtek(TM) Supreme Flowable Composites for Class IV and Veneers
A NA study of Dental Restoration and Dental Veneers, sponsored by New York University.
- Recruiting
- Registry status
- NA
- Development phase
- 75
- Enrollment target
- 1
- Study location
NCT07128589: Recruiting NA study of Dental Restoration and Dental Veneers, sponsored by New York University.
NCT07128589 is a NA study of Dental Restoration and Dental Veneers that is actively recruiting participants, run by New York University. The registered enrollment target is 75 participants, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT07128589, a NA study of Dental Restoration and Dental Veneers, is actively recruiting participants, sponsored by New York University.
- RECRUITING
- Registry status
- NA
- Development phase
- 75 participants
- Enrollment target
- 1
- Study location
Study Summary
This clinical study aims to evaluate the clinical performance of 3M™ Filtek™ Supreme Flowable Composite in class IV and veneer indication. Follow-ups of 7 days, 6, 12, and 24 months will be conducted following an Fédération Dentaire Internationale (FDI) modified score (2023). A minimum of 50 Class IV and 25 veneers will be included in the evaluation. Research data and pictures will be provided for each patient pre-op and at 7 days (baseline, 6 months, 12 months and 24 months. Evaluation will be conducted by two calibrated evaluators different from the operator according to FDI clinical criteria.
Primary Outcome
Primary site survival will be based off of an Modified FDI criteria score greater or equal to 4.
Conditions Studied
Interventions
- DEVICE 3MTM FiltekTM Supreme Flowable Composite
Study Locations (1)
New York
- NYU College Of Dentistry - New York
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 75 participants |
| Start Date | 2025-08-07 |
| Est. Completion | 2028-09 |
| Phase | NA |
What NCT07128589 shows while recruiting
NCT07128589 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 75 participants, a relatively small participant target, below the 1,404-participant average among 58,714 other NA trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Dental Restoration appearing as the primary indexed condition, and to 1 intervention - of which 3MTM FiltekTM Supreme Flowable Composite is the first listed.
NCT07128589 reports a single indexed study location in New York.
Frequently Asked Questions
What is clinical trial NCT07128589 about?
NCT07128589 is a clinical study titled "3M(TM) Filtek(TM) Supreme Flowable Composites for Class IV and Veneers". This clinical study aims to evaluate the clinical performance of 3M™ Filtek™ Supreme Flowable Composite in class IV and veneer indication. Follow-ups of 7 days, 6, 12, and 24 months will be conducted following an Fédération Dentaire Internationale (FDI) modified score (2023). A minimum of 50 Class I...
What is the current status of trial NCT07128589?
This trial is currently recruiting. It is a NA study. The enrollment target is 75 participants. The study started on 2025-08-07. Estimated completion is 2028-09.
What conditions does trial NCT07128589 study?
This clinical trial studies the following conditions: Dental Restoration, Dental Veneers.
What interventions are being tested in trial NCT07128589?
The interventions under investigation include: 3MTM FiltekTM Supreme Flowable Composite (DEVICE).
Who is sponsoring clinical trial NCT07128589?
This trial is sponsored by New York University, which has 83 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07128589 being conducted?
This trial has 1 study location across New York. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT07128589's enrollment target sits among peer trials
75 1069th of 2000 higher than 919 of 2,000 other NA trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other NA trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01535430 · 75 participants
Assessment of Eloquent Function in Brain Tumor Patients
- NCT01542879 · 75 participants · Phase 1
Development of Radiation Free Whole Body Magnetic Resonance (MR) Imaging Technique for Staging Children With Cancer
- NCT02232191 · 75 participants · Phase 2
Immunologic Response to Pneumococcal Polysaccharide Vaccine in Splenic Injury Patients
- NCT02754544 · 75 participants · NA
Electrocorticography in Mapping Functional Brain Areas During Surgery in Patients With Brain Tumors
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI